| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
The new and advantageous Ca2+ antagonist chemical ginsenoside Ro found in ginseng has the potential to prevent thrombotic disorders caused by platelet aggregation. Thrombin-stimulated platelet aggregation is dose-dependently inhibited by ginsenoside Ro, with an IC50 of about 155 μM [1]. Thrombin-induced platelet aggregation is prevented by ginsenoside Ro, which also suppresses the synthesis of TXA2. Platelet aggregation and thrombosis are facilitated by thromboxane A2 (TXA). Thrombin-induced TXB2 levels can be decreased dose-dependently (50-300 μM) by ginsenoside Ro; thrombin-mediated elevation of TXB2 levels can be inhibited by 94.9% at 300 μM. The protein COX-1 activity was 2.3 ± 0.1 nmol/mg when ginsenoside Ro (negative control) was depleted. The activity of COX-1 was, however, dose-dependently diminished by ginsenoside Ro (50–300 μM); at 300 μM, the activity of COX-1 was 26.4% lower than that of the negative control. The activity of TXA2 synthase (TXAS) was 220.8±1.8 ng/mg protein/min in the absence of ginsenoside Ro (negative control). In contrast, TXAS activity dropped by 22.9% at 300 μM relative to the negative control when ginsenoside Ro was added in a dose-dependent manner (50-300 μM). In comparison to its inhibitory effect on COX-1 (26.4%) and TXAS (22.9%) activities, ginsenoside Ro (300 μM) has a far greater effect on TXB2 production (94.9%) [2]. At 10 μM, 50 μM, 100 μM, and 200 μM concentrations, ginsenoside Ro was first treated for 24 hours in order to assess its toxicity in Raw 264.7 cells. No clear dose-dependent toxicity was observed in ginsenoside Ro. The impact of ginsenoside Ro on oxidative stress indicators (ROS) levels and cell viability were then assessed following an exposure to 1 μg/mL LPS. Approximately 70% less cells were viable after exposure to LPS than after no treatment. The viability of the cells was greatly increased by pretreating them with 100 μM and 200 μM ginsenoside Ro for one hour before incubating them with 1 μg/mL LPS for 24 hours. Ginsenoside Ro's effects on vitality are compatible with changes in ROS levels and NO generation [3].
|
|---|---|
| ln Vivo |
Prior to intravenous injection of HT29, mice were given water-soluble ginsenoside Ro by gavage at doses of 25 and 250 mg/kg/day for four days in order to maintain blood concentrations of ginsenoside Ro. The mice were then given ginsenoside Ro intravenously for 40 days after the level was reached. Following a 38-day course of therapy, the animals were slaughtered, and HT29 assessed the toxicity of ginsenoside Ro and mouse histology in addition to counting the number of lung metastases. With an 88% (P < 0.01) inhibition rate, ginsenoside Ro (250 mg/kg/day) can dramatically lower the amount of tumor nodules on the lung surface [4].
|
| References |
|
| Additional Infomation |
Chikusetsusaponin-V is a triterpenoid saponin. It has a role as a metabolite.
Ginsenoside Ro has been reported in Panax pseudoginseng, Panax japonicus, and other organisms with data available. See also: Asian Ginseng (part of). |
| Molecular Formula |
C48H76O19
|
|---|---|
| Molecular Weight |
957.12
|
| Exact Mass |
956.498
|
| CAS # |
34367-04-9
|
| PubChem CID |
11815492
|
| Appearance |
White to off-white solid powder
|
| Density |
1.14
|
| Boiling Point |
1018.6±65.0 °C at 760 mmHg
|
| Melting Point |
241 °C
|
| Flash Point |
289.2±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.627
|
| LogP |
6.29
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
67
|
| Complexity |
1880
|
| Defined Atom Stereocenter Count |
23
|
| SMILES |
C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O
|
| InChi Key |
NFZYDZXHKFHPGA-QQHDHSITSA-N
|
| InChi Code |
InChI=1S/C48H76O19/c1-43(2)14-16-48(42(61)67-40-35(58)31(54)29(52)24(20-50)63-40)17-15-46(6)21(22(48)18-43)8-9-26-45(5)12-11-27(44(3,4)25(45)10-13-47(26,46)7)64-41-37(33(56)32(55)36(65-41)38(59)60)66-39-34(57)30(53)28(51)23(19-49)62-39/h8,22-37,39-41,49-58H,9-20H2,1-7H3,(H,59,60)/t22-,23+,24+,25-,26+,27-,28+,29+,30-,31-,32-,33-,34+,35+,36-,37+,39-,40-,41+,45-,46+,47+,48-/m0/s1
|
| Chemical Name |
(2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,12aS,14aR,14bR)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4-dihydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-2-carboxylic acid
|
| Synonyms |
Chikusetsusaponin V; Chikusetsusaponin 5; Ginsenoside Ro
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~104.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0448 mL | 5.2240 mL | 10.4480 mL | |
| 5 mM | 0.2090 mL | 1.0448 mL | 2.0896 mL | |
| 10 mM | 0.1045 mL | 0.5224 mL | 1.0448 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
